WO2016055160A3 - New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases - Google Patents

New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases Download PDF

Info

Publication number
WO2016055160A3
WO2016055160A3 PCT/EP2015/001974 EP2015001974W WO2016055160A3 WO 2016055160 A3 WO2016055160 A3 WO 2016055160A3 EP 2015001974 W EP2015001974 W EP 2015001974W WO 2016055160 A3 WO2016055160 A3 WO 2016055160A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
various diseases
cell
signal transduction
transduction pathway
Prior art date
Application number
PCT/EP2015/001974
Other languages
French (fr)
Other versions
WO2016055160A2 (en
Inventor
Jean-Marc Combette
Catherine Deloche
Original Assignee
Xigen Inflammation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/002724 external-priority patent/WO2015197098A1/en
Priority claimed from PCT/EP2015/001294 external-priority patent/WO2015197194A2/en
Priority to PCT/EP2015/001974 priority Critical patent/WO2016055160A2/en
Priority to EP15778614.6A priority patent/EP3204031A2/en
Priority to US15/516,943 priority patent/US11779628B2/en
Application filed by Xigen Inflammation Ltd. filed Critical Xigen Inflammation Ltd.
Publication of WO2016055160A2 publication Critical patent/WO2016055160A2/en
Priority to US15/737,480 priority patent/US20180170983A1/en
Priority to EP16733432.5A priority patent/EP3313428A1/en
Priority to CN201680037307.6A priority patent/CN107969126A/en
Priority to CA2987365A priority patent/CA2987365A1/en
Priority to JP2017566407A priority patent/JP2018525337A/en
Priority to PCT/EP2016/064765 priority patent/WO2016207413A1/en
Publication of WO2016055160A3 publication Critical patent/WO2016055160A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)

Abstract

The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.
PCT/EP2015/001974 2013-06-26 2015-10-08 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases WO2016055160A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/EP2015/001974 WO2016055160A2 (en) 2014-10-08 2015-10-08 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP15778614.6A EP3204031A2 (en) 2014-10-08 2015-10-08 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US15/516,943 US11779628B2 (en) 2013-06-26 2015-10-08 Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
PCT/EP2016/064765 WO2016207413A1 (en) 2015-06-26 2016-06-24 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
JP2017566407A JP2018525337A (en) 2013-06-26 2016-06-24 Novel use of cell-permeable peptide inhibitors of the JNK signaling pathway for the treatment of mild cognitive impairment
US15/737,480 US20180170983A1 (en) 2015-06-26 2016-06-24 New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
CA2987365A CA2987365A1 (en) 2015-06-26 2016-06-24 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
EP16733432.5A EP3313428A1 (en) 2015-06-26 2016-06-24 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
CN201680037307.6A CN107969126A (en) 2015-06-26 2016-06-24 The cell-penetrating inhibitor peptides of JNK signal transduction pathways are used for the new application for treating mild cognitive impairment

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/002724 2014-10-08
PCT/EP2014/002724 WO2015197098A1 (en) 2014-06-26 2014-10-08 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EPPCT/EP2015/001294 2015-06-26
PCT/EP2015/001294 WO2015197194A2 (en) 2014-06-26 2015-06-26 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PCT/EP2015/001974 WO2016055160A2 (en) 2014-10-08 2015-10-08 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Publications (2)

Publication Number Publication Date
WO2016055160A2 WO2016055160A2 (en) 2016-04-14
WO2016055160A3 true WO2016055160A3 (en) 2016-06-30

Family

ID=54292770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/001974 WO2016055160A2 (en) 2013-06-26 2015-10-08 New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Country Status (2)

Country Link
EP (1) EP3204031A2 (en)
WO (1) WO2016055160A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049188A1 (en) * 1997-04-28 1998-11-05 University Of Massachusetts Inhibitors of the jnk signal transduction pathway and methods of use
WO2004037196A2 (en) * 2002-10-24 2004-05-06 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010065850A2 (en) * 2008-12-04 2010-06-10 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
US20120101046A1 (en) * 2009-03-30 2012-04-26 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206564A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1994008598A1 (en) 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Liver reserve cells
US6184038B1 (en) 1995-07-28 2001-02-06 Marie Curie Cancer Care Transport proteins and their uses
US6610820B1 (en) 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049188A1 (en) * 1997-04-28 1998-11-05 University Of Massachusetts Inhibitors of the jnk signal transduction pathway and methods of use
WO2004037196A2 (en) * 2002-10-24 2004-05-06 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010065850A2 (en) * 2008-12-04 2010-06-10 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
US20120101046A1 (en) * 2009-03-30 2012-04-26 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013091896A1 (en) * 2011-12-21 2013-06-27 Xigen Inflammation Ltd. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206564A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUGAN C ET AL: "Role of c-Jun N-Terminal Kinase (JNK) Activation in Micturition Reflexes in Cyclophosphamide (CYP)-Induced Cystitis in Female Rats", JOURNAL OF MOLECULAR NEUROSCIENCE, vol. 54, no. 3, November 2014 (2014-11-01), pages 360 - 369, XP002752705 *

Also Published As

Publication number Publication date
EP3204031A2 (en) 2017-08-16
WO2016055160A2 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
WO2014206563A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
MX2014006399A (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome.
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2007031280A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
JOP20220242A1 (en) Nucleic acids encoding antibodies specifically binding to masp-3
WO2015197194A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PT2491942E (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various cardiovascular diseases
WO2015002754A3 (en) Novel bicyclic bromodomain inhibitors
EP3936141A3 (en) Anti-senescence compounds and uses thereof
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
WO2015138394A3 (en) Hppd variants and methods of use
PH12015502698A1 (en) Dual selective pi3 delta and gamma kinase inhibitors
WO2015148620A3 (en) Peptide inhibitors of bcr-abl oligomerization
EA202091567A1 (en) CHIMERIC PROTEINS MIT
WO2016066726A3 (en) Active acrylamides
EA201692038A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION
WO2016145362A3 (en) Inhibitors of dek protein and related methods
WO2016055160A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PH12017502345A1 (en) Novel thrombin inhibitors
WO2016075305A3 (en) Peptides derived from acinetobacter baumannii and their use in vaccination
MX2020006533A (en) Inhibitors of protease activated receptor-2.
LT3484907T (en) Novel phosphotriazole mrna 5`-end cap analogs, composition comprising the same, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule, protein or peptide
WO2016027285A3 (en) Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors
WO2015171395A3 (en) Degradation resistant peptide based biosensors
AU2013263786B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15778614

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15516943

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015778614

Country of ref document: EP